{
  "company": "Novartis",
  "data_source": "https://www.novartis.com/research-development/novartis-pipeline",
  "extraction_date": "2025-07-03",
  "pipeline_overview": {
    "description": "Benefiting from our continued focus on innovation, Novartis has one of the industry's most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide.",
    "therapeutic_areas": [
      "Oncology: Solid Tumors",
      "Oncology: Hematology",
      "Immunology",
      "Neuroscience",
      "In-market Brands and Global Health"
    ],
    "development_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3",
      "Registration"
    ]
  },
  "pipeline_candidates": [
    {
      "compound": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Gastroenteropancreatic neuroendocrine tumors",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 3",
      "mechanism": "Radioligand therapy target SSTR"
    },
    {
      "compound": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "GEPNET, pediatrics",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 2",
      "mechanism": "Radioligand therapy target SSTR"
    },
    {
      "compound": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Glioblastoma",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 2",
      "mechanism": "Radioligand therapy target SSTR"
    },
    {
      "compound": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "1L ES-SCLC",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 2",
      "mechanism": "Radioligand therapy target SSTR"
    },
    {
      "compound": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Gastroenteropancreatic neuroendocrine tumors (GEP-NET), 1st line in G2/3 tumors",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Registration",
      "filing_date": "2024",
      "mechanism": "Radioligand therapy target SSTR"
    },
    {
      "compound": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Breast cancer",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 1",
      "filing_date": "≥ 2028",
      "mechanism": "Radioligand therapy target GRPR"
    },
    {
      "compound": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Glioblastoma multiforme",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 1",
      "filing_date": "≥ 2028",
      "mechanism": "Radioligand therapy target GRPR",
      "lead_indication": true
    },
    {
      "compound": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Multiple solid tumors",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 2",
      "filing_date": "≥ 2028",
      "mechanism": "Radioligand therapy target GRPR"
    },
    {
      "compound": "AAA614",
      "brand_name": "AAA614",
      "indication": "Solid tumors",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 2",
      "mechanism": "Radioligand therapy target FAP",
      "lead_indication": true
    },
    {
      "compound": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Metastatic hormone sensitive prostate cancer (mHSPC)",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 3",
      "filing_date": "2025",
      "mechanism": "Radioligand therapy target PSMA"
    },
    {
      "compound": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Oligometastatic prostate cancer",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 3",
      "filing_date": "2027",
      "mechanism": "Radioligand therapy target PSMA"
    },
    {
      "compound": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Metastatic neuroendocrine prostate cancer",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 1",
      "filing_date": "2025",
      "mechanism": "Radioligand therapy target PSMA"
    },
    {
      "compound": "AAA802",
      "brand_name": "225Ac-PSMA-R2",
      "indication": "Prostate cancer",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 1",
      "mechanism": "Radioligand therapy target PSMA",
      "lead_indication": true
    },
    {
      "compound": "AAA817",
      "brand_name": "225Ac-PSMA-617",
      "indication": "Metastatic castration-resistant prostate cancer",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 1",
      "mechanism": "Radioligand therapy target PSMA",
      "lead_indication": true
    },
    {
      "compound": "ABL001",
      "brand_name": "Scemblix®",
      "indication": "Chronic myeloid leukemia, pediatrics",
      "therapeutic_area": "Oncology: Hematology",
      "phase": "Phase 2",
      "mechanism": "BCR-ABL inhibitor"
    },
    {
      "compound": "AIN457",
      "brand_name": "Cosentyx®",
      "indication": "Giant cell arteritis (GCA)",
      "therapeutic_area": "Immunology",
      "phase": "Phase 3",
      "filing_date": "2025",
      "mechanism": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
      "supplementary_indication": true
    },
    {
      "compound": "AIN457",
      "brand_name": "Cosentyx®",
      "indication": "Polymyalgia rheumatica",
      "therapeutic_area": "Immunology",
      "phase": "Phase 3",
      "filing_date": "2026",
      "mechanism": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)"
    },
    {
      "compound": "AMG334",
      "brand_name": "Aimovig®",
      "indication": "Migraine, pediatrics",
      "therapeutic_area": "In-market Brands and Global Health",
      "phase": "Phase 3",
      "filing_date": "2027",
      "mechanism": "CGRPR antagonist"
    },
    {
      "compound": "BAF312",
      "brand_name": "Mayzent®",
      "indication": "Multiple sclerosis, pediatrics",
      "therapeutic_area": "Neuroscience",
      "phase": "Phase 3",
      "filing_date": "2027",
      "mechanism": "S1P1 Modulator (Sphingosine-1-phosphate receptor modulator)",
      "supplementary_indication": true
    },
    {
      "compound": "BYL719",
      "brand_name": "Vijoyce®",
      "indication": "Lymphatic malformations",
      "therapeutic_area": "Oncology: Solid Tumors",
      "phase": "Phase 3",
      "filing_date": "2027",
      "mechanism": "PI3K-alpha inhibitor"
    }
  ],
  "key_focus_areas": {
    "radioligand_therapy": {
      "description": "Novartis has a strong focus on radioligand therapy with multiple candidates targeting different receptors",
      "targets": ["SSTR", "GRPR", "FAP", "PSMA"],
      "compounds": ["AAA601 (Lutathera®)", "AAA603 (177Lu-NeoB)", "AAA614", "AAA617 (Pluvicto®)", "AAA802", "AAA817"]
    },
    "oncology": {
      "description": "Strong pipeline in both solid tumors and hematology",
      "focus_areas": ["Prostate cancer", "Neuroendocrine tumors", "Glioblastoma", "Breast cancer", "Chronic myeloid leukemia"]
    },
    "immunology": {
      "description": "Pipeline includes treatments for autoimmune and inflammatory conditions",
      "focus_areas": ["Giant cell arteritis", "Polymyalgia rheumatica"]
    },
    "neuroscience": {
      "description": "Focus on neurological conditions including multiple sclerosis and migraine",
      "focus_areas": ["Multiple sclerosis", "Migraine"]
    }
  },
  "combination_abbreviations": {
    "fulv": "fulvestrant",
    "tmx": "tamoxifen",
    "gsn": "goserelin",
    "NSAI": "Non-steroidal aromatase inhibitor",
    "Taf": "Tafinlar® (dabrafenib)",
    "Mek": "Mekinist® (trametinib)"
  },
  "filing_status_codes": {
    "a": "EU filing, approved in US",
    "b": "US filing, approved in EU",
    "c": "US filing, submitted in EU",
    "d": "US pending submission, approved in EU",
    "e": "EU filing, submitted in US"
  },
  "total_candidates": "Over 100 projects in clinical development",
  "data_update_frequency": "Quarterly",
  "last_updated": "2024 Annual Report"
}
